Atenativ Effect on Uterine Blood Flow and Preeclampsia
Status:
Withdrawn
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The study will be an open controlled pilot study of 6 patients with early-onset severe
preeclampsia. Patients will receive Atenativ in addition to conventional therapy The patients
will be followed up within the study until three days after delivery. Laboratory analyses and
uterine and umbiliacal blood flow will be determined.